NCT05194163View on ClinicalTrials.gov

MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

November 30, 2024

Conditions
Alzheimer Disease
Interventions
DRUG

MW150

oral-delivered capsule of study drug

DRUG

Placebo

oral delivered capsule matched to study drug capsule

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

Sponsors
All Listed Sponsors
collaborator

Columbia University

OTHER

collaborator

National Institute on Aging (NIA)

NIH

lead

Neurokine Therapeutics

INDUSTRY